Join our daily newsletter At The Bell to receive exclusive market insights
- Clarity Pharmaceuticals (CU6) is advancing its theranostic prostate cancer trial to its third cohort, prescribing its highest dose yet of Cu SAR-bisPSMA
- The company’s novel candidate drug is being used to treat metastatic castrate-resistant prostate cancer
- With no dose-limiting toxicities witnessed in cohort two, Clarity is given the green light from the safety review committee (SRC) to create a third cohort
- Recruitment opens at US clinical sites, with patients currently undergoing screening, and a cohort three dose level of 12GBq is being used in a dose escalation phase
- CU6 shares are up 2.27 per cent, trading at 90 cents at 12:13 pm AEST
Clarity Pharmaceuticals (CU6) has accelerated its theranostic prostate cancer trial, moving into its third cohort and administering the highest dose yet of Cu SAR-bisPSMA.
The company’s innovative candidate drug, aimed at treating metastatic castrate-resistant prostate cancer (mCRPC), was administered to three participants in cohort two at a dosage of 8GBq.
The data from cohort two underscores the positive impact of the 8GBq dose of Cu SAR-bisPSMA on all patients, showcasing a significant reduction in prostate-specific antigen (PSA) levels within weeks of a single dose.
Following the absence of dose-limiting toxicities in cohort two, Clarity has received approval from the safety review committee (SRC) to elevate the dosage and examine its effects in a third cohort.
“SAR-bisPSMA aims to be a best-in-class PSMA product due to its differentiation from all other PSMA-targeted products in the market and in development that only have a single PSMA-targeting agent,” CU6 Executive Chairperson Dr Alan Taylor.
“We purposely designed and optimised SAR-bisPSMA to have two PSMA-targeting agents to address the challenges of low uptake and retention that the first generation of PSMA products suffer from.”
Recruitment is underway at US clinical sites, with patients currently undergoing screening. The third cohort will receive a dose level of 12GBq in a dose escalation phase.
CU6 shares were up 2.27 per cent, trading at 90 cents at 12:13 pm AEST.
